Holen Sie sich die Stockscreener-App
3.07
19.69%
0.505
Handel nachbörslich:
3.07
Schlusskurs vom Vortag:
$2.565
Offen:
$2.75
24-Stunden-Volumen:
96,244
Relative Volume:
4.52
Marktkapitalisierung:
$4.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-560.20K
KGV:
-2.1172
EPS:
-1.45
Netto-Cashflow:
$-6.90M
1W Leistung:
+14.13%
1M Leistung:
+15.81%
6M Leistung:
-27.76%
1J Leistung:
-52.77%
1-Tages-Spanne:
$2.75
$3.15
1-Wochen-Bereich:
$2.52
$3.15
52-Wochen-Spanne:
$2.32
$8.775
Synaptogenix Inc Stock (SNPX) Company Profile
Firmenname
Synaptogenix Inc
Sektor
Branche
Telefon
(973) 242-0005
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Vergleichen Sie SNPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNPX
Synaptogenix Inc
|
3.07 | 4.16M | 0 | -560.20K | -6.90M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Synaptogenix Inc Aktie (SNPX) Neueste Nachrichten
Synaptogenix forms committee to explore strategic opportunities - Investing.com
Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa
Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India
Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada
Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK
Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com
Synaptogenix announces new preferred stock series - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com India
Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World
Synaptogenix extends preferred shares maturity date - Investing.com
Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix - The Pharma Letter
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
New collab to probe potential of fatty acid analogs in Alzheimer's - The Pharma Letter
Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix begins pre-clinical trials for SCI treatment - Investing.com
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - Lelezard
Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to “Buy” - Defense World
Synaptogenix (NASDAQ:SNPX) Trading Down 0.5% - Defense World
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
Synaptogenix Acquires 25% Stake In Cannasoul - Quantisnow
FDA grants IND authorisation for Synaptogenix's multiple sclerosis trial - Yahoo Finance
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Dana Incorporated names Lisa Amend as new HR Chief By Investing.com - Investing.com South Africa
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - StockTitan
Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024TipRanks.com - TipRanks
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
Finanzdaten der Synaptogenix Inc-Aktie (SNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):